The United Kingdom authorized Pfizer’s coronavirus vaccine for emergency use Wednesday, becoming the first country to authorize a vaccine backed by promising clinical trial results.
The vaccine, developed in partnership with the Germany drug maker BioNTech, is set to begin distribution across Britain next week, the government said in a release. The initial batch of approximately 800,000 doses will go to health care workers, nursing home residents and other elderly people, according to NBC News.
“It’s fantastic,” U.K. Prime Minister Boris Johnson said Wednesday. “It’s the protection of vaccines that will ultimately allow us to reclaim our lives and get the economy moving again.”
His message was echoed by Matt Hancock, Britain’s Health Secretary, who said the country that “help is on its way.”
Help is on its way.
The MHRA has formally authorised the Pfizer/BioNTech vaccine for Covid-19.
The NHS stands ready to start vaccinating early next week.
The UK is the first country in the world to have a clinically approved vaccine for supply.
— Matt Hancock (@MattHancock) December 2, 2020
The announcement is likely to be followed by similar ones in the United States, as Pfizer and Moderna have both applied for emergency use authorization from the FDA. (RELATED: First Plane With Vaccines Lands In Chicago As Limited US Distribution Begins)
Pfizer CEO Albert Broula applauded the U.K.’s decision in a release Wednesday, saying that “Authorization is a goal we have been working toward since we first declared that science will win.”
Pfizer’s vaccine candidate was the first of three that showed to be at least 90% effective in clinical trials, preceding vaccines from Moderna and AstraZeneca.
The coronavirus has infected over 1.6 million people in the United Kingdom and killed nearly 60,000, according to a Johns Hopkins University database. Worldwide, the virus has infected over 64 million people and killed nearly 1.5 million.
All content created by the Daily Caller News Foundation, an independent and nonpartisan newswire service, is available without charge to any legitimate news publisher that can provide a large audience. All republished articles must include our logo, our reporter’s byline and their DCNF affiliation. For any questions about our guidelines or partnering with us, please contact firstname.lastname@example.org.